122 related articles for article (PubMed ID: 27354603)
21. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
[TBL] [Abstract][Full Text] [Related]
22. Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer.
Miše BP; Telesmanić VD; Tomić S; Šundov D; Čapkun V; Vrdoljak E
Pathol Oncol Res; 2015 Apr; 21(2):347-56. PubMed ID: 25108408
[TBL] [Abstract][Full Text] [Related]
23. Effect of ALDH1 on prognosis and chemoresistance by breast cancer subtype.
Kida K; Ishikawa T; Yamada A; Shimada K; Narui K; Sugae S; Shimizu D; Tanabe M; Sasaki T; Ichikawa Y; Endo I
Breast Cancer Res Treat; 2016 Apr; 156(2):261-9. PubMed ID: 26975188
[TBL] [Abstract][Full Text] [Related]
24. Expression Patterns of Nrf2 and Keap1 in Ovarian Cancer Cells and their Prognostic Role in Disease Recurrence and Patient Survival.
Cho HY; Kim K; Kim YB; Kim H; No JH
Int J Gynecol Cancer; 2017 Mar; 27(3):412-419. PubMed ID: 28129239
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological and Prognostic Significance of Cancer Stem Cell Markers in Ovarian Cancer Patients: Evidence from 52 Studies.
Tao Y; Li H; Huang R; Mo D; Zeng T; Fang M; Li M
Cell Physiol Biochem; 2018; 46(4):1716-1726. PubMed ID: 29730663
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome.
Hashimoto K; Shimizu C; Tsuda H; Saji S; Osaki A; Shigekawa T; Aogi K
Oncology; 2012; 82(3):168-74. PubMed ID: 22433454
[TBL] [Abstract][Full Text] [Related]
27. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
[TBL] [Abstract][Full Text] [Related]
28. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer.
da Costa AA; Valadares CV; Baiocchi G; Mantoan H; Saito A; Sanches S; Guimarães AP; Achatz MI
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S971-8. PubMed ID: 26014155
[TBL] [Abstract][Full Text] [Related]
30. Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.
Ricci F; Fratelli M; Guffanti F; Porcu L; Spriano F; Dell'Anna T; Fruscio R; Damia G
Oncotarget; 2017 Jan; 8(5):7441-7451. PubMed ID: 26910918
[TBL] [Abstract][Full Text] [Related]
31. Isolation and characterization of cancer stem cells from high-grade serous ovarian carcinomas.
He QZ; Luo XZ; Wang K; Zhou Q; Ao H; Yang Y; Li SX; Li Y; Zhu HT; Duan T
Cell Physiol Biochem; 2014; 33(1):173-84. PubMed ID: 24504111
[TBL] [Abstract][Full Text] [Related]
32. ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling.
Meng E; Mitra A; Tripathi K; Finan MA; Scalici J; McClellan S; Madeira da Silva L; Reed E; Shevde LA; Palle K; Rocconi RP
PLoS One; 2014; 9(9):e107142. PubMed ID: 25216266
[TBL] [Abstract][Full Text] [Related]
33. ALDH1 expression correlates with favorable prognosis in ovarian cancers.
Chang B; Liu G; Xue F; Rosen DG; Xiao L; Wang X; Liu J
Mod Pathol; 2009 Jun; 22(6):817-23. PubMed ID: 19329942
[TBL] [Abstract][Full Text] [Related]
34. Correlation of ALDH1, CD44, OCT4 and SOX2 in tongue squamous cell carcinoma and their association with disease progression and prognosis.
Huang CF; Xu XR; Wu TF; Sun ZJ; Zhang WF
J Oral Pathol Med; 2014 Aug; 43(7):492-8. PubMed ID: 24450601
[TBL] [Abstract][Full Text] [Related]
35. Evolution of platinum resistance in high-grade serous ovarian cancer.
Cooke SL; Brenton JD
Lancet Oncol; 2011 Nov; 12(12):1169-74. PubMed ID: 21742554
[TBL] [Abstract][Full Text] [Related]
36. New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools.
Muñoz-Galván S; Felipe-Abrio B; García-Carrasco M; Domínguez-Piñol J; Suarez-Martinez E; Verdugo-Sivianes EM; Espinosa-Sánchez A; Navas LE; Otero-Albiol D; Marin JJ; Jiménez-García MP; García-Heredia JM; Quiroga AG; Estevez-Garcia P; Carnero A
J Exp Clin Cancer Res; 2019 Jun; 38(1):234. PubMed ID: 31159852
[TBL] [Abstract][Full Text] [Related]
37. ALDH1 expression indicates chemotherapy resistance and poor outcome in node-negative rectal cancer.
Avoranta ST; Korkeila EA; Ristamäki RH; Syrjänen KJ; Carpén OM; Pyrhönen SO; Sundström JT
Hum Pathol; 2013 Jun; 44(6):966-74. PubMed ID: 23332924
[TBL] [Abstract][Full Text] [Related]
38. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment.
Resetkova E; Reis-Filho JS; Jain RK; Mehta R; Thorat MA; Nakshatri H; Badve S
Breast Cancer Res Treat; 2010 Aug; 123(1):97-108. PubMed ID: 19911270
[TBL] [Abstract][Full Text] [Related]
39. ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome.
Surowiak P; Materna V; Kaplenko I; Spaczynski M; Dolinska-Krajewska B; Gebarowska E; Dietel M; Zabel M; Lage H
Clin Cancer Res; 2006 Dec; 12(23):7149-58. PubMed ID: 17145840
[TBL] [Abstract][Full Text] [Related]
40. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
